MBX Biosciences, Inc.
MBX
$10.29
-$0.205-1.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 45.58% | 53.04% | 47.55% | 104.61% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 86.27% | 79.19% | 108.04% | 109.11% | |
| Operating Income | -86.27% | -79.19% | -108.04% | -109.11% | |
| Income Before Tax | -76.25% | -78.53% | -108.43% | -107.38% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -76.25% | -78.53% | -108.43% | -107.38% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -76.25% | -78.53% | -108.43% | -107.38% | |
| EBIT | -86.27% | -79.19% | -108.04% | -109.11% | |
| EBITDA | -86.45% | -79.16% | -108.27% | -109.57% | |
| EPS Basic | 93.96% | 70.37% | -64.32% | -47.76% | |
| Normalized Basic EPS | 93.58% | 70.37% | -64.32% | -47.76% | |
| EPS Diluted | 93.96% | 70.37% | -64.32% | -47.76% | |
| Normalized Diluted EPS | 93.58% | 70.37% | -64.32% | -47.76% | |
| Average Basic Shares Outstanding | 2,817.40% | 502.57% | 26.85% | 40.35% | |
| Average Diluted Shares Outstanding | 2,817.40% | 502.57% | 26.85% | 40.35% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |